Victoza vs. Glimepiride

See how Victoza and Glimepiride compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Victoza is a once-daily injectable GLP-1 receptor agonist that also lowers cardiovascular risk, while glimepiride is a once-daily oral sulfonylurea that only targets blood sugar.

  • Glimepiride carries a real risk of hypoglycemia and costs far less than Victoza, but Victoza tends to cause fewer blood sugar lows and can support modest weight loss.

  • Both drugs are approved only for type 2 diabetes, not type 1, and both require gradual dose increases to reduce side effects.

Victoza vs. Glimepiride Drug Summary

Victoza

Victoza (liraglutide) is a GLP-1 receptor agonist injected once daily to improve blood sugar control in adults and children 10 and older with type 2 diabetes. It also carries an FDA approval to reduce major cardiovascular events in adults with type 2 diabetes and existing heart disease. Treatment starts at a low dose that is increased over the first few weeks to limit nausea.

Glimepiride

Glimepiride is an oral sulfonylurea taken once daily to help adults with type 2 diabetes control blood sugar as an adjunct to diet and exercise. It works by prompting the pancreas to release more insulin, with the dose raised gradually from 1 mg up to a maximum of 8 mg. It has been available since 1995 and is one of the most affordable diabetes medications on the market.

Victoza vs. Glimepiride Side Effects

Victoza

Most common
Diarrhea (up to 11.7%)
Nausea (≥5%)
Vomiting (≥5%)
Decreased appetite (≥5%)

Glimepiride

Most common
Hypoglycemia (>5%)
Dizziness (>5%)
Asthenia (>5%)
Headache (>5%)

Victoza vs. Glimepiride Dosage

Victoza

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 0.6 mg once daily Week 1
Maximum dose 1.8 mg once daily Week 3 onward
Dose changes 2 increases Every week

Glimepiride

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 1 mg once daily At the start
Maximum dose 8 mg once daily If needed
Dose changes 3 increases As tolerated

Victoza vs. Glimepiride Indications

Victoza

Victoza is FDA-approved to improve blood sugar control in type 2 diabetes for adults and children 10 and older, alongside diet and exercise. It also carries an approval to reduce the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes and known heart disease. It is not approved for type 1 diabetes.

  • Adjunct to diet and exercise for type 2 diabetes

  • Approved for children 10 years and older

  • Reduces risk of major cardiovascular events

  • Not approved for type 1 diabetes

Glimepiride

Glimepiride is FDA-approved to help control blood sugar in adults with type 2 diabetes, used together with diet and exercise. It does not carry a cardiovascular risk-reduction indication and is not approved for type 1 diabetes or diabetic ketoacidosis. It is typically used only in adults.

  • Adjunct to diet and exercise for type 2 diabetes

  • Approved only for adults

  • No cardiovascular risk-reduction indication

  • Not approved for type 1 diabetes or DKA

Victoza vs. Glimepiride Pros and Cons

Victoza

Victoza offers cardiovascular protection and a lower risk of hypoglycemia than sulfonylureas, but it requires a daily injection and carries a boxed warning for thyroid tumor risk seen in animal studies. Insurance coverage and cost can be significant barriers for many patients.

Pros

  • Reduces risk of major cardiovascular events

  • Low risk of causing hypoglycemia on its own

  • Often leads to modest weight loss

  • Approved for children 10 and older

Cons

  • Requires a daily self-injection

  • Boxed warning for thyroid C-cell tumor risk

  • Common gastrointestinal side effects like nausea

  • Roughly $935 to $1,470 per month without insurance

Glimepiride

Glimepiride is an affordable, well-established oral option, but it carries a real risk of hypoglycemia and has been linked to increased cardiovascular mortality in older studies. It has no cardiovascular benefit indication and does not typically cause weight loss.

Pros

  • Taken as a pill, no injections needed

  • Roughly $10 to $20 per month without insurance

  • Long track record dating back to 1995

  • Simple, predictable oral dosing

Cons

  • Higher risk of hypoglycemia than Victoza

  • Possible increased cardiovascular mortality risk

  • No cardiovascular protective indication

  • Can cause weight gain

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.